You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,486,204

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,486,204

Title:	Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
Abstract:	A COX-2 selective inhibiting drug is disclosed as useful in treating or preventing prostate cancer. The compound is used alone or in combination with other drugs.
Inventor(s):	Waldstreicher; Joanne (Scotch Plains, NJ), Morrison; Briggs W. (Watchung, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	09/771,315
Patent Claims:	1. A method of treating or preventing prostate cancer in a male mammalian patient in need thereof, comprising administering to said patient a COX-2 selective inhibiting compound in an amount that is effective to treat or prevent prostate cancer, wherein the COX-2 selective inhibiting compound is rofecoxib. 2. A method of treating or preventing prostate cancer in accordance with claim 1 wherein the patient is a human. 3. A method in accordance with claim 1 further comprising administering to the patient a 5-alpha reductase inhibitor. 4. A method in accordance with claim 1 wherein the 5-alpha reductase inhibitor is selected from the group consisting of: finasteride, dutasteride and epristeride. 5. A method of treating or preventing prostate cancer in a male mammalian patient comprising administering to the patient rofecoxib in combination with radiation therapy. 6. A method in accordance with claim 5 wherein the radiation therapy comprises external radiation or radioactive seed implantation. 7. A method of treating or preventing prostate cancer in accordance with claim 1 wherein the COX-2 selective inhibiting compound is administered in combination with selenium. 8. A method of treating or preventing prostate cancer in accordance with claim 1 wherein the COX-2 selective inhibiting compound is administered in combination with vitamin C or E. 9. A method of treating or preventing prostate cancer in accordance with claim 1 wherein the COX-2 selective inhibiting compound is administered in combination with at least one drug selected from the group consisting of: alkylating agents, antibiotics, hormones, anti-hormones, LHRH analogs and antagonists, anti-metabolites and miscellaneous anti-cancer agents. 10. A method of treating or preventing prostate cancer in accordance with claim 9 wherein the COX-2 selective inhibiting compound is administered in combination with at least one drug selected from the group consisting of: Myleran.RTM. (busulfan), Platinol.RTM. (cisplatin), Alkeran.RTM. (melphalan hydrochloride), Cytoxan.RTM. (cyclophosphamide), Leukeran.RTM. (chlorambucil), BiCNU.RTM. (carmustine), CeeNU.RTM. (lomustine [CCNU]), Mustargen.RTM. (mechloroethamine hydrochloride), Adriamycin.RTM. (doxorubicin hydrochloride), Blenoxane.RTM. (bleomycin sulfate), Cerubidine.RTM. (daunorubicin hydrochloride), Cosmegen.RTM. (dactinomycin), Mithracin.RTM. (plicamycin), Mutamycin.RTM. (mitomycin), Novantrone.RTM. (mitoxantrone hydrochloride), progesterone, estrogen, Estrace.RTM. (estradiol), DES, Casodex.RTM. (bicalutamide), Eulexin.RTM. (flutamide), Nilandrone.RTM. (nilutamide), Synarel.RTM. (nafarelin acetate), Lupron.RTM. (leuprolide acetate), Zoladex.RTM. (goserelin acetate), Histerelin.RTM., ganirelix, cetrorelix, aberelix, Cytosar.RTM. (cytarabine), Fludura.RTM. (fludarabine phosphate), Leustatin.RTM. (cladribine), methotrexate, Purinethol.RTM. (mercaptopurine), thioguanine, Camptosar.RTM. (irinotecan hydrochloride), Celestone.RTM. (betamethasone), DTIC.RTM. (dacarbazine), Elspar.RTM. (asparaginase), Gemzar.RTM. (gemcitabine hydrochloride), Hexalen.RTM. (altretamine), Hycamtin.RTM. (topotecan hydrochloride), Hydrea.RTM. (hydroxyurea), interferon A, Navelbine.RTM. (vinorelbine tartrate), Oncaspar.RTM. (pegaspargase), Oncovin.RTM. (vincristine sulfate), Proleukin.RTM. (aldesleukin), Rituxan.RTM. (rituximab), Rimaxin.RTM., Taxol.RTM. (paclitaxel) and Velban.RTM. (vinblastine sulfate).

Details for Patent 6,486,204

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2020-01-28
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992	⤷ Try a Trial	2020-01-28
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994	⤷ Try a Trial	2020-01-28
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2020-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.